Correlation of CYP2B6 , CYP2C19 , ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

Abstract CYP2B6 , CYP2C19 , ABCC4 , and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment. 110 BMT patients who received high dose CPA treatment were genotyped for variants in these genes and the results were correlated with toxicity and relapse....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia research 2012-01, Vol.36 (1), p.59-66
Hauptverfasser: Black, John L, Litzow, Mark R, Hogan, William J, O’Kane, Dennis J, Walker, Denise L, Lesnick, Timothy G, Kremers, Walter K, Avula, Rajeswari, Ketterling, Rhett P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract CYP2B6 , CYP2C19 , ABCC4 , and SOD2 have been implicated in adverse drug reactions and survival after cyclophosphamide (CPA) treatment. 110 BMT patients who received high dose CPA treatment were genotyped for variants in these genes and the results were correlated with toxicity and relapse. CYP2B6 genotype significantly influenced overall toxicity suggesting active CYP2B6 alleles led to higher rates of overall toxicity. The p.R487C deficiency allele was significantly associated with a lower rate of overall toxicity and a higher rate of relapse. SOD2 rs4880 V16A polymorphism was associated with significantly less CPA-related overall toxicity and significantly lower relapse rates by Kaplan–Meier analysis although the SOD2 finding regarding relapse was not significant when evaluated by the cumulative incidence function.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2011.06.020